“…Various attempts have been made to prepare type II mechanism-based inhibitors of this enzyme (14,15,19,21), which would be activated by the enzyme's catalytic activity and inactivate the enzyme through covalent modification. This type of mechanism-based inhibitor, starting with relatively unreactive structures that are activated only by specific targeted enzymes, often have better pharmacological specificity (29).…”